Drug Trial Radar · NCT00693199
Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
Last checked: Nov 20, 2026Latest source record: Aug 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Jul 2006
Primary completion
Oct 2006
Study completion Oct 2006
Sponsor
- Lead sponsor
- Anhui Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The University of Science and Technology of China; Peking University First Hospital
- First posted
- Jun 6, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study was to investigate the efficacy and safety of low dose amlodipine alone, or combined with low dose terazosin in male patients with both lower urinary tract symptoms and hypertension.
Conditions
- Lower Urinary Tract Symptoms
- Hypertension
Interventions
amlodipineDrug
amlodipine 5mg once daily for 28 days
terazosinDrug
terazosin 2 mg once daily for 28 days
amlodipine plus terazosinDrug
amlodipine 5 mg plus terazosin 2 mg once daily for 28days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy outcomes were reductions in blood pressure and International Prostate Symptoms Score (IPSS) and sub-scores.Time frame: 28th day after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Biomedicine Inistitute of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.